Back to Authors

Stephens, Elizabeth H.

https://orcid.org/0000-0001-8593-1290

Mayo Clinic

Mayo Clinic

Citations 3

Ebstein anomaly update: the evolution of care and the revolution of surgical strategy
Jamal, Tamer, Stephens, Elizabeth H. , Swan, Elena Ashikhmina , Weatherhead, Jeffrey R, Dearani, Joseph A., Taggart, Nathan, Qureshi, M. Yasir , Swan, Elena A, Taggart, Nathaniel W. , Weatherhead, Jeffrey , Dearani, Joseph A.

Expert Review of Cardiovascular Therapy | August 15, 2025 | Volume: 23 | Issue: 9 | Pages: 493-505

10.1080/14779072.2025.2544817 Get It

Management of Isolated, Congenital Anterior Mitral Valve Cleft
Hargiss, J. Blade , Stephens, Elizabeth H. , Taggart, Nathaniel W , Dearani, Joseph A. , Taggart, Nathaniel W.

World Journal for Pediatric and Congenital Heart Surgery | December 17, 2021 | Volume: 13 | Issue: 1 | Pages: 60-64

10.1177/21501351211061261 Get It

Background: Isolated anterior mitral valve clefts (MVC) are rare congenital heart defects, and data are limited regarding the natural history and surgical outcomes for such isolated MVCs. Methods: We conducted a retrospective review of patients with congenital MVC who were evaluated at Mayo Clinic in Rochester, Minnesota between 1993 and 2020. Patients were separated into two cohorts: those who underwent surgical repair of the MVC and those who had not yet undergone repair. Baseline and postoperative clinical and echocardiographic data were analyzed. Results: Fourteen patients were included in the nonsurgical cohort and eight patients in the surgical cohort. Surgical repair was via primary median sternotomy (n = 6) or robot-assisted, minimally invasive (n = 2). All cleft repairs were performed by simple suture closure. Intraoperative evaluation of the clefts did not reveal additional structural factors that could account for the mitral regurgitation (MR). At latest follow-up of the surgical cohort, the median grade of MR was 1 (range 0-1), and median left ventricular ejection fraction was 65% (IQR 59%-67%), both similar to the immediate postoperative result. At latest follow-up, all patients in the nonsurgical cohort were NYHA Class 1, and median MR grade was 1. All patients were asymptomatic (NYHA Class 1). Conclusions: Our findings corroborate prior reports that MVC repair is safe and successful and is followed by a low rate of recurrent mitral valve dysfunction. Durable surgical repair of isolated, congenital MVC can be performed safely in select patients. The decision to intervene should be based on the severity of mitral regurgitation and patient symptoms rather than the presence of the MVC alone.
Systemic Semilunar Valve Repair/Replacement With Fontan Circulation: The Mayo Clinic Experience
Graham, Gabriel, Phillips, Amanda L., Stephens, Elizabeth H. , Cetta, Frank , Niaz, Talha , O'Leary, Patrick W, Dearani, Joseph A. , O’Leary, Patrick

World Journal for Pediatric and Congenital Heart Surgery | November 30, 2021 | Volume: 12 | Issue: 6 | Pages: 739-744

10.1177/21501351211044131 Get It

Background: There is a paucity of literature regarding systemic semilunar valve (SSLV) dysfunction in patients with Fontan circulation. We sought to describe our center's 47-year experience with systemic semilunar valve replacement or repair (SSLVR) in patients with Fontan circulation. Methods: The Mayo Clinic Fontan Database is a comprehensive institutional database that stores clinical information of 1176 patients from 1973 to 2021. It was reviewed to identify patients who had a SSLV intervention at the time of or after Fontan. A cohort of 15 patients was identified and a retrospective review of their records was performed. Results: Fourteen patients had SSLV replacement (all mechanical) and one had a repair. SSLVR occurred up to 29 years following the Fontan (mean 11.3 ± 9 years, median 14 years). Thirteen of 14 with SSLVR were performed after Fontan and one was done at the time of initial Fontan. This was an older cohort and mean age at the time of Fontan was 8.7 ± 9.4 years (median 4 years). Indication for the operation was > moderate SSLV regurgitation in all patients. Six patients had decreased ventricular function (EF < 50%) prior to SSLVR and 8 had reduced function after SSLVR. Conclusion: Fortunately, the need for SSLV intervention after Fontan was rare, as evidenced by our small cohort extracted from a large single-institution database spanning a 47-year time period. Reduced preoperative and postoperative ejection fraction was common but did not seem to impact the outcome. Optimal timing for SSLV intervention after Fontan remains unclear.